Clinical features, risk of mass enlargement, and development of endocrine hyperfunction in patients with adrenal incidentalomas: a long-term follow-up study.
ACS
AI
Adrenal
Adrenal incidentaloma
Autonomous cortisol secretion
Cushing’s syndrome
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
09
06
2020
accepted:
23
08
2020
pubmed:
12
9
2020
medline:
9
7
2021
entrez:
11
9
2020
Statut:
ppublish
Résumé
To evaluate the risk of mass enlargement and endocrine function modification in patients with adrenal incidentaloma (AI). In this retrospective study, we examined clinical and hormonal characteristics of 310 patients with AI (200 females and 110 males; age: 58.3 ± 12.9 years), followed up for a median (interquartile range) of 31.4 months (13.0-78.6) and evaluated for possible modification in adrenal mass size and hormonal function. The hormonal evaluation included morning serum cortisol and plasma ACTH at 8 a.m., aldosterone, plasma renin activity/direct renin concentration, and 24-h urine metanephrines/normetanephrines. One microgram overnight dexamethasone suppression test (DST) was performed. Autonomous cortisol secretion (ACS) was diagnosed in the presence of cortisol after 1 mg DST > 5 μg/dl (138 nmol/l) or >1.8 and ≤5 μg/dl (50-138 nmol/l) and at least one of the following: (i) low ACTH; (ii) increased 24-h urinary-free cortisol; (iii) absence of cortisol rhythm; and (iv) post-LDDST cortisol level > 1.8 μg/dl (50 nmol/l). When there was no biochemical evidence of adrenal hormonal hyperactivity, AIs were classified as nonfunctioning (NFAIs). The mass was considered significantly enlarged when the size increase was more than 20% and at least 5 mm compared to baseline. At diagnosis, NFAIs were found in 209 patients, while ACS and overt adrenal hyperfunction were diagnosed in 81 and 20 patients, respectively. During follow-up, 3.3% and 1.5% of patients with NFAI developed subtle and overt endocrine hyperfunction, respectively, while a significant mass enlargement was observed in 17.7% of all AIs. The risk of developing ACS was significantly higher in patients with adenoma >28 mm (hazard ratio [HR] 12.4; 95% confidence interval [CI], 2.33-66.52, P = 0.003), in those with bilateral adrenal tumors (HR: 5.36; 95% CI, 1.17-24.48, P = 0.030), and with low/suppressed ACTH values (HR: 11.2, 95% CI 2.06-60.77; P = 0.005). The risk of mass enlargement was lower for patients in the fourth quartile of body mass index than those in the first quartile (HR 0.33; 95% CI, 0.14-0.78; P = 0.012). In patients with AI, the risk of developing hormonal hyperfunction and mass enlargement is overall low, although some tumor characteristics and anthropometric features might increase this risk. Taking account of all these aspects is important for planning a tailored follow-up in AI patients.
Identifiants
pubmed: 32915435
doi: 10.1007/s12020-020-02476-1
pii: 10.1007/s12020-020-02476-1
pmc: PMC7835305
doi:
Substances chimiques
Hydrocortisone
WI4X0X7BPJ
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
178-188Références
R.T. Kloos, M.D. Gross, I.R. Francis, M. Korobkin, B. Shapiro, Incidentally discovered adrenal masses. Endocr. Rev. 16, 460–484 (1995)
pubmed: 8521790
L. Barzon, N. Sonino, F. Fallo, G. Palù, M. Boscaro, Prevalence and natural history of adrenal incidentalomas. Eur. J. Endocrinol. 149, 273–285 (2003)
pubmed: 14514341
W.F. Young, Clinical practice. The incidentally discovered adrenal mass. N. Engl. J. Med. 356, 601–610 (2007)
pubmed: 17287480
R. Giordano, E. Marinazzo, R. Berardelli, A. Picu, M. Maccario, E. Ghigo, E. Arvat, Long-term morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal incidentalomas. Eur. J. Endocrinol. 162, 779–785 (2010)
pubmed: 20103607
C. Davenport, A. Liew, B. Doherty, H.H.N. Win, H. Misran, S. Hanna, D. Kealy, F. Al-Nooh, A. Agha, C.J. Thompson, M. Lee, D. Smith, The prevalence of adrenal incidentaloma in routine clinical practice. Endocrine 40, 80–83 (2011)
pubmed: 21547511
G. Reimondo, E. Castellano, M. Grosso, R. Priotto, S. Puglisi, A. Pia, M. Pellegrino, G. Borretta, M. Terzolo, Adrenal incidentalomas are tied to increased risk of diabetes: findings from a prospective study. J. Clin. Endocrinol. Metab. 105, 1–9 (2020)
M.M. Grumbach, B.M.K. Biller, G.D. Braunstein, K.K. Campbell, J.Aidan Carney, P.A. Godley, E.L. Harris, J.K.T. Lee, Y.C. Oertel, M.C. Posner, J.A. Schlechte, S. Wieand, K. Marciel, Management of the clinically inapparent adrenal mass (‘incidentaloma’). Ann. Intern. Med. 138, 424–429 (2003)
pubmed: 12614096
M. Reincke, Subclinical Cushing’s syndrome. Endocrinol. Metab. Clin. North Am. 29, 43–56 (2000)
pubmed: 10732263
F. Mantero, M. Terzolo, G. Arnaldi, G. Osella, A.M. Masini, A. Alì, M. Giovagnetti, G. Opocher, A. Angeli, A survey on adrenal incidentaloma in Italy. J. Clin. Endocrinol. Metab. 85, 637–644 (2000)
pubmed: 10690869
R. Nawar, D. Aron, Adrenal incidentalomas—a continuing management dilemma. Endocr. Relat. Cancer 12, 585–598 (2005)
pubmed: 16172193
I. Chiodini, Diagnosis and treatment of subclinical hypercortisolism. J. Clin. Endocrinol. Metab. 96, 1223–1236 (2011)
pubmed: 21367932
M. Debono, M. Bradburn, M. Bull, B. Harrison, R.J. Ross, J. Newell-Price, Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J. Clin. Endocrinol. Metab. 99, 4462–4470 (2014)
pubmed: 25238207
pmcid: 4255126
L. Tauchmanovà, R. Rossi, B. Biondi, M. Pulcrano, V. Nuzzo, E.A. Palmieri, S. Fazio, G. Lombardi, Patients with subclinical Cushing’s syndrome due to adrenal adenoma have increased cardiovascular risk. J. Clin. Endocrinol. Metab. 87, 4872–4878 (2002)
pubmed: 12414841
G. Di Dalmazi, R. Pasquali, F. Beuschlein, M. Reincke, Subclinical hypercortisolism: a state, a syndrome, or a disease? Eur. J. Endocrinol. 173, M61–M71 (2015)
pubmed: 26282599
T.J. Cawood, P.J. Hunt, D. O’Shea, D. Cole, S. Soule, Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur. J. Endocrinol. 161, 513–527 (2009)
pubmed: 19439510
J.I. Mechanick, D.A. Bergman, S.S. Braithwaite, P.J. Palumbo, American Association of Clinical Endocrinologists protocol for standardized production of clinical practice guidelines. Endocr. Pract. 10, 353–361 (2004)
pubmed: 15776523
M.A. Zeiger, G.B. Thompson, Q.Y. Duh, A.H. Hamrahian, P. Angelos, D. Elaraj, E. Fishman, J. Kharlip, The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocr. Pract. 14, 1–20 (2009)
M. Fassnacht, W. Arlt, I. Bancos, H. Dralle, J. Newell-Price, A. Sahdev, A. Tabarin, M. Terzolo, S. Tsagarakis, O.M. Dekkers, Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur. J. Endocrinol. 175, G1–G34 (2016)
pubmed: 27390021
M.F. Piepoli, A.W. Hoes, S. Agewall, C. Albus, C. Brotons, A.L. Catapano, M.T. Cooney, U. Corrà, B. Cosyns, C. Deaton, I. Graham, M.S. Hall, F.D.R. Hobbs, M.L. Løchen, H. Löllgen, P. Marques-Vidal, J. Perk, E. Prescott, J. Redon, D.J. Richter, N. Sattar, Y. Smulders, M. Tiberi, H.B. Van Der Worp, I. Van Dis, W.M.M. Verschuren, S. Binno, G. De Backer, M. Roffi, V. Aboyans, N. Bachl, S. Carerj, L. Cho, J. Cox, J. De Sutter, G. Egidi, M. Fisher, D. Fitzsimons, O.H. Franco, M. Guenoun, C. Jennings, B. Jug, P. Kirchhof, K. Kotseva, G.Y.H. Lip, F. Mach, G. Mancia, F.M. Bermudo, A. Mezzani, A. Niessner, P. Ponikowski, B. Rauch, A. Stauder, G. Turc, O. Wiklund, S. Windecker, J.L. Zamorano, S. Achenbach, L. Badimon, G. Barón-Esquivias, H. Baumgartner, J.J. Bax, V. Dean, Ç. Erol, O. Gaemperli, P. Kolh, P. Lancellotti, P. Nihoyannopoulos, A. Torbicki, A.V. Carneiro, B. Metzler, R. Najafov, V. Stelmashok, C. De Maeyer, M. Dilić, I. Gruev, D. Miličić, H. Vaverkova, I. Gustafsson, I. Attia, D. Duishvili, J. Ferrières, N. Kostova, Z. Klimiashvili, R. Hambrecht, K. Tsioufis, E. Szabados, K. Andersen, C. Vaughan, B. Zafrir, S. Novo, K. Davletov, F. Jashari, A. Kerimkulova, I. Mintale, G. Saade, Z. Petrulioniene, C. Delagardelle, C.J. Magri, V. Rudi, L. Oukerraj, B.E. Çölkesen, H. Schirmer, R.P.Dos Reis, D. Gherasim, S. Nedogoda, M. Zavatta, V. Giga, S. Filipova, L.R. Padial, A. Kiessling, A. Mahdhaoui, D. Ural, E. Nesukay, C. Gale, 2016 European guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 37, 2315–2381 (2016)
pubmed: 27222591
pmcid: 4986030
American Diabetes Association, 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2020. Diabetes Care 43, S14 LP–S14 31 (2002)
J.M. Lee, M.K. Kim, S.H. Ko, J.M. Koh, B.Y. Kim, S.W. Kim, S.K. Kim, H.J. Kim, O.H. Ryu, J. Park, J.S. Lim, S.Y. Kim, Y.K. Shong, S.J. Yoo, Clinical guidelines for the management of adrenal incidentaloma. Endocrinol. Metab. 32, 300–218 (2017)
G. Arnaldi, M. Boscaro, Adrenal incidentaloma. Best Pract. Res. Clin. Endocrinol. Metab. 26, 405–419 (2012)
pubmed: 22863384
V. Morelli, G. Reimondo, R. Giordano, S. Della Casa, C. Policola, S. Palmieri, A.S. Salcuni, A. Dolci, M. Mendola, M. Arosio, B. Ambrosi, A. Scillitani, E. Ghigo, P. Beck-Peccoz, M. Terzolo, I. Chiodini, Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. J. Clin. Endocrinol. Metab. 99, 827–834 (2014)
pubmed: 24423350
R. Giordano, F. Guaraldi, R. Berardelli, I. Karamouzis, V. D’Angelo, E. Marinazzo, A. Picu, E. Ghigo, E. Arvat, Glucose metabolism in patients with subclinical Cushing’s syndrome. Endocrine 41, 415–423 (2012)
pubmed: 22391939
M. Terzolo, A. Pia, A. Alì, G. Osella, G. Reimondo, S. Bovio, F. Daffara, M. Procopio, P. Paccotti, G. Borretta, A. Angeli, Adrenal incidentaloma: a new cause of the metabolic syndrome? J. Clin. Endocrinol. Metab. 87, 998–1003 (2002)
pubmed: 11889151
Y.S. Elhassan, F. Alahdab, A. Prete, D.A. Delivanis, A. Khanna, L. Prokop, M.H. Murad, M.W. O’Reilly, W. Arlt, I. Bancos, Natural History of Adrenal Incidentalomas with and without mild autonomous cortisol excess: a systematic review and meta-analysis. Ann. Intern. Med. 171, 107–116 (2019)
pubmed: 31234202
J.D. Pasternak, C.D. Seib, N. Seiser, J.B. Tyrell, C. Liu, R.M. Cisco, J.E. Gosnell, W.T. Shen, I. Suh, Q.Y. Duh, Differences between bilateral adrenal incidentalomas and unilateral lesions. JAMA Surg. 150, 974–978 (2015)
pubmed: 26200882
E. Vassilatou, A. Vryonidou, D. Ioannidis, S.A. Paschou, M. Panagou, I. Tzavara, Bilateral adrenal incidentalomas differ from unilateral adrenal incidentalomas in subclinical cortisol hypersecretion but not in potential clinical implications. Eur. J. Endocrinol. 171, 37–45 (2014)
pubmed: 24743396
H. Olsen, E. Nordenström, A. Bergenfelz, U. Nyman, S. Valdemarsson, E. Palmqvist, Subclinical hypercortisolism and CT appearance in adrenal incidentalomas: a multicenter study from Southern Sweden. Endocrine 42, 164–173 (2012)
pubmed: 22350586
P. Falcetta, F. Orsolini, E. Molinaro, P. Vitti, M. Tonacchera, Tako-tsubo syndrome as first manifestation in a case of pheochromocytoma developed from a non-functional adrenal incidentaloma. Front. Endocrinol. 11, 51 (2020)
G.P. Bernini, A. Moretti, C. Oriandini, M. Bardini, C. Taurino, A. Salvetti, Long-term morphological and hormonal follow-up in a single unit on 115 patients with adrenal incidentalomas. Br. J. Cancer 92, 1104–1109 (2005)
pubmed: 15770213
pmcid: 2361933
R. Libè, C. Dall’Asta, L. Barbetta, A. Baccarelli, P. Beck-Peccoz, B. Ambrosi, Long-term follow-up study of patients with adrenal incidentalomas. Eur. J. Endocrinol. 147, 489–494 (2002)
pubmed: 12370111
M. Terzolo, S. Bovio, G. Reimondo, A. Pia, G. Osella, G. Borretta, A. Angeli, Subclinical Cushing’s syndrome in adrenal incidentalomas. Endocrinol. Metab. Clin. North Am. 34, 423–439 (2005)
pubmed: 15850851
M. Terzolo, G. Osella, A. Alì, G. Borretta, F. Cesario, P. Paccotti, A. Angeli, Subclinical Cushing’s syndrome in adrenal incidentaloma. Clin. Endocrinol. 48, 89–97 (1998)
L. Barzon, C. Scaroni, N. Sonino, F. Fallo, A. Paoletta, M. Boscaro, Risk factors and long-term follow-up of adrenal incidentalomas. J. Clin. Endocrinol. Metab. 84, 520–526 (1999)
pubmed: 10022410
M. Terzolo, A. Stigliano, I. Chiodini, P. Loli, L. Furlani, G. Arnaldi, G. Reimondo, A. Pia, V. Toscano, M. Zini, G. Borretta, E. Papini, P. Garofalo, B. Allolio, B. Dupas, F. Mantero, A. Tabarin, Italian Association of Clinical Endocrinologists, AME position statement on adrenal incidentaloma. Eur. J. Endocrinol. 164, 851–870 (2011)
pubmed: 21471169
E. Vassilatou, A. Vryonidou, S. Michalopoulou, J. Manolis, J. Caratzas, C. Phenekos, I. Tzavara, Hormonal activity of adrenal incidentalomas: results from a long-term follow-up study. Clin. Endocrinol. 70, 674–679 (2009)
S. Yener, S. Ertilav, M. Secil, T. Demir, B. Akinci, L. Kebapcilar, A. Comlekci, F. Bayraktar, S. Yesil, Prospective evaluation of tumor size and hormonal status in adrenal incidentalomas. J. Endocrinol. Investig. 33, 32–36 (2010)
A. Comlekci, S. Yener, S. Ertilav, M. Secil, B. Akinci, T. Demir, L. Kebapcilar, F. Bayraktar, S. Yesil, S. Eraslan, Adrenal incidentaloma, clinical, metabolic, follow-up aspects: Single centre experience. Endocrine 37, 40–46 (2010)
pubmed: 19882253
L. Barzon, F. Fallo, N. Sonino, M. Boscaro, Development of overt Cushing’s syndrome in patients with adrenal incidentaloma. Eur. J. Endocrinol. 146, 61–66 (2002)
pubmed: 11751069
F.C. Fagour, S. Bardet, V. Rohmer, Y. Arimone, P. Lecomte, N. Valli, A. Tabarin, Usefulness of adrenal scintigraphy in the follow-up of adrenocortical incidentalomas: a prospective multicenter study. Eur. J. Endocrinol. 60, 257–264 (2009)
Y. Erbil, E. Ademoǧlu, N. Özbey, U. Barbaros, B.T. Yanik, A. Salmaslioǧlu, A. Bozbora, S. Özarmaǧan, Evaluation of the cardiovascular risk in patients with subclinical Cushing syndrome before and after surgery. World J. Surg. 30, 1665–1671 (2006)
pubmed: 16927063
S.A. Paschou, E. Kandaraki, F. Dimitropoulou, D.G. Goulis, A. Vryonidou, Subclinical Cushing’s syndrome in patients with bilateral compared to unilateral adrenal incidentalomas: a systematic review and meta-analysis. Endocrine 51, 225–235 (2016)
pubmed: 26498946
W.F. Young, H. Du Plessis, G.B. Thompson, C.S. Grant, D.R. Farley, M.L. Richards, D. Erickson, A. Vella, A.W. Stanson, J.A. Carney, C.F. Abboud, P.C. Carpenter, The clinical conundrum of corticotropin-independent autonomous cortisol secretion in patients with bilateral adrenal masses. World J. Surg. 32, 856–862 (2008)
pubmed: 18074172
B. Bülow, S. Jansson, C. Juhlin, L. Steen, M. Thorén, H. Wahrenberg, S. Valdemarsson, B. Wängberg, B. Ahrén, Adrenal incidentaloma—follow up results from a Swedish prospective study. Eur. J. Endocrinol. 154, 419–423 (2006)
pubmed: 16498055
A.Y. Kargi, G. Iacobellis, Adipose tissue and adrenal glands: Novel pathophysiological mechanisms and clinical applications. Int. J. Endocrinol. 2014, 614074 (2014)
pubmed: 25018768
pmcid: 4075085
L. Paschke, T. Zemleduch, M. Rucinski, A. Ziolkowska, M. Szyszka, L.K. Malendowicz, Adiponectin and adiponectin receptor system in the rat adrenal gland: ontogenetic and physiologic regulation, and its involvement in regulating adrenocortical growth and steroidogenesis. Peptides 31, 1715–1724 (2010)
pubmed: 20600433
Y. Arita, S. Kihara, N. Ouchi, M. Takahashi, K. Maeda, J.I. Miyagawa, K. Hotta, I. Shimomura, T. Nakamura, K. Miyaoka, H. Kuriyama, M. Nishida, S. Yamashita, K. Okubo, K. Matsubara, M. Muraguchi, Y. Ohmoto, T. Funahashi, Y. Matsuzawa, Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257, 79–83 (1999)
pubmed: 10092513
Y.T. Yamauchi, J. Kamon, H. Waki, Y. Terauchi, N. Kubota, K. Hara, Y. Mori, T. Ide, K. Murakami, N. Tsuboyama-Kasaoka, O. Ezaki, Y. Akanuma, O. Gavrilova, C. Vinson, M.L. Reitman, H. Kagechika, K. Shudo, M. Yoda, Y. Nakano, K. Tobe, R. Nagai, S. Kimura, M. Tomita, P. Froguel, T. Kadowaki, The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7, 941–946 (2001)
pubmed: 11479627
S.R. Bornstein, K. Uhlmann, A. Haidan, M. Ehrhart-Bornstein, W.A. Scherbaum, Evidence for a novel peripheral action of leptin as a metabolic signal to the adrenal gland: Leptin inhibits cortisol release directly. Diabetes 46, 1235–1238 (1997)
pubmed: 9200662
K.M. Kruse, S.R. Bornstein, K. Uhlmann, G. Paeth, W.A. Scherbaum, Leptin down-regulates the steroid producing system in the adrenal. Endocr. Res. 24, 587–590 (1998)
pubmed: 9888542
M.L. Heiman, R.S. Ahima, L.S. Craft, B. Schoner, T.W. Stephens, J.S. Flier, Leptin inhibition of the hypothalamic-pituitary-adrenal axis in response to stress. Endocrinology 138, 3859–3863 (1997)
pubmed: 9275075
pmcid: 9275075
J.F. Tong, X. Yan, M.J. Zhu, S.P. Ford, P.W. Nathanielsz, M. Du, Maternal obesity downregulates myogenesis and β-catenin signaling in fetal skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 296, E917–E924 (2009)
S.C. Manolagas, M. Almeida, Gone with the Wnts: β-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol. Endocrinol. 21, 2605–2614 (2007)
pubmed: 17622581
M.A.G. Essers, L.M.M. De Vries-Smits, N. Barker, P.E. Polderman, B.M.T. Burgering, H.C. Korswagen, Functional interaction between β-catenin and FOXO in oxidative stress signaling. Science 308, 1181–1184 (2005)
pubmed: 15905404
D. Hoogeboom, M.A.G. Essers, P.E. Polderman, E. Voets, L.M.M. Smits, B.M.T. Burgering, Interaction of FOXO with β-catenin inhibits β-catenin/T cell factor activity. J. Biol. Chem. 283, 9224–9230 (2008)
pubmed: 18250171